Cardiotoxicity of Prostate Cancer Therapy: Mechanisms, Predictors, and Social Determinants of Health in Prostate Cancer Patients Treated With Androgen Deprivation Therapy (PCT)

NCT05096338 ACTIVE_NOT_RECRUITING

This is an observational study for patients with prostate cancer that will be treated with Androgen Deprivation Therapy. The study will help the investigators learn more about how these medications affect the heart and how those effects relate to patients' medical history and social determinants of health (such as race, gender identity, education, occupation, access to health services and economic resources). Patients on this study will have echocardiograms, blood draws, and answer questions about their symptoms and activity level. Patients will be followed on this study for up to 5 years.

Details

Lead sponsor	Abramson Cancer Center at Penn Medicine
Status	ACTIVE_NOT_RECRUITING
Enrolment	200
Start date	2021-10-27
Completion	2029-11

Conditions

• Prostate Cancer
• Cardiotoxicity
• Drug-Related Side Effects and Adverse Reactions
• Cardiovascular Diseases

Interventions

• Social Determinants of Health

Primary outcomes

• Change in Left Ventricular Ejection Fraction (LVEF) — through study completion (expected to be 15 years)
  Absolute change in LVEF by echocardiogram at follow-up

Countries

United States